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Abstract Although the incidence of cancer increases with
age, older patients are under-represented in cancer treatment
trials, resulting in limited data availability in this patient
population. Here we present results from pre-defined sub-
group analyses conducted by age group (\65 vs C65 years)
from a randomized, double-blind, placebo-controlled phase
III trial in patients with HER2-positive metastatic breast
cancer. Patients who had not received previous chemother-
apy or biological therapy for HER2-positive locally recur-
rent, unresectable or metastatic breast cancer were randomly
assigned to treatment with placebo, trastuzumab, and doce-
taxel or with pertuzumab, trastuzumab, and docetaxel. Pri-
mary endpoint was independently assessed progression-free
survival. We performed pre-specified subgroup analyses of
progression-free survival according to age. The study is
registered with ClinicalTrials.gov, NCT00567190. 808
patients were enrolled. Of those, 127 patients were 65 years
of age or older (placebo arm: 67, pertuzumab arm: 60).
Patients in both age groups experienced progression-free
survival benefit with treatment in the pertuzumab arm
(\65 years: HR: 0.65; 95 % CI 0.53–0.80; C65 years: HR:
0.52; 95 % CI 0.31–0.86). Diarrhoea, fatigue, asthenia,
decreased appetite, vomiting, and dysgeusia were reported
more frequently in patients 65 years of age or older com-
pared with younger patients. Neutropenia and febrile neu-
tropenia were reported less frequently in the older age group.
The efficacy and safety data reported in CLEOPATRA
suggest that the combined use of pertuzumab, trastuzumab,
and docetaxel should not be limited by patient age.
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Introduction
Cancer is an age-related disease and the probability of
developing breast cancer is highest in women 70 years of
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age or older [1]. Given the changing population demo-
graphics, the overall incidence of breast cancer will rise,
driven by cancer diagnosed in older patients [2, 3], high-
lighting the importance of treatment guidelines for this
patient population. In a US-based study Hutchins et al. [4]
reported that although the estimated proportion of women
C65 years of age with breast cancer is 49 %, they only
represent 9 % of the patients participating in clinical trials.
This discrepancy and the resulting scarcity of level I evi-
dence leads to uncertainties about best practice in older
patients, especially since older patients generally present
with more comorbidities and related medications than
younger patients [5–7], increasing the complexity of their
management. Although survival rates of patients with breast
cancer C65 years of age in the US have increased over an
observation period from 1977 to 2006 [8], several popula-
tion-based studies have shown that older patients are fre-
quently not treated according to standard of care [7, 9–11],
with adverse consequences on survival outcomes [12, 13].
Results from a prospective, observational US-based study
in patients with HER2-positive metastatic breast cancer
showed that elderly patients present with higher rates of
underlying cardiovascular disease and are less likely to
receive cytotoxic anti-cancer therapies compared with
younger patients [14]. Trastuzumab-based treatment resul-
ted in a survival benefit in all age groups compared with
trastuzumab-free therapy [14]. Similarly, in HER2-positive
early breast cancer, trastuzumab-based therapy significantly
improved disease-free [15] and overall survival [16] com-
pared with chemotherapy alone. In an exploratory analysis
from the same study, age (B40 vs[40 years) was not sig-
nificantly associated with disease-free or overall survival,
either in the trastuzumab arm or in the observation arm [17].
This analysis was limited by a relatively short median fol-
low-up of 2 years, which was chosen to avoid bias intro-
duced by cross-over to the trastuzumab arm [17].
We performed a randomized, double-blind, placebo-
controlled phase III study to investigate the efficacy and
safety of pertuzumab, trastuzumab, and docetaxel com-
pared with placebo, trastuzumab, and docetaxel in patients
with HER2-positive first-line metastatic breast cancer.
Progression-free survival was significantly improved with
pertuzumab, trastuzumab, and docetaxel [18], and this
combination was first approved in June 2012 by the US
FDA for first-line treatment of HER2-positive metastatic
breast cancer. After one additional year of follow-up, the
overall survival benefit with pertuzumab, trastuzumab, and
docetaxel had reached statistical significance, demonstrat-
ing a clinically meaningful improvement compared with
trastuzumab and docetaxel [19]. In CLEOPATRA, 16 %
(n = 127) of patients were 65 years of age or older. Here
we report efficacy and safety analyses in older patients
compared with those in patients \65 years of age.
Methods
Study design and treatment
Study details have been published previously [18, 19].
CLEOPATRA was a randomized, double-blind, placebo-
controlled phase III trial designed with two treatment arms:
placebo, trastuzumab (Herceptin, F. Hoffmann-La Roche,
Basel, Switzerland) and docetaxel (Taxotere, Sanofi-
Aventis, Paris, France) (referred to as placebo arm); and
pertuzumab (Perjeta, F. Hoffmann-La Roche), trast-
uzumab and docetaxel (referred to as pertuzumab arm).
Primary endpoint was progression-free survival, defined as
the time from randomization to disease progression, con-
firmed by an independent review facility according to
Response Evaluation Criteria in Solid Tumors (RECIST)
[20] or death from any cause within 18 weeks of the
patient’s last tumour assessment. Secondary endpoints
included overall survival, progression-free survival by
investigator assessment, objective response rate and safety.
All study drugs were administered intravenously during a
3-weekly cycle. Pertuzumab/placebo was given at 840 mg
in cycle 1, followed by 420 mg in every subsequent cycle.
Trastuzumab loading dose was 8 mg/kg in cycle 1 and
6 mg/kg for subsequent cycles. Dose modifications of
pertuzumab and trastuzumab were not permitted. Doce-
taxel was given at 75 mg/m2. Docetaxel dose escalation to
100 mg/m2 was allowed if tolerated; two docetaxel dose
reductions by 25 % to 75 or 55 mg/m2 were allowed in
order to manage toxicities. Pertuzumab/placebo and trast-
uzumab were administered until investigator-assessed dis-
ease progression or unmanageable toxicity. At least six
cycles of docetaxel were recommended; fewer cycles were
allowed in the event of disease progression or unmanage-
able toxicity, more cycles at the discretion of the treating
physician.
The study was conducted according to Good Clinical
Practice and the Declaration of Helsinki. Protocol approval
was obtained from an independent ethics committee at each
participating site. All patients provided written informed
consent.
Patients
Patients with HER2-positive (by central confirmation)
locally recurrent, unresectable, or metastatic breast cancer
who had not received prior chemotherapy or biological
therapy for their advanced disease were eligible. Further
inclusion criteria were measurable and/or non-measurable
disease, a baseline left ventricular ejection fraction (LVEF)
of at least 50 %, an Eastern Cooperative Oncology Group
(ECOG) performance status [21] of 0 or 1, a disease-free
interval of at least 12 months between completion of
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systemic treatment (excluding hormonal therapy) and
diagnosis of metastatic disease, and a minimum age of
18 years. Exposure to trastuzumab during neoadjuvant and
adjuvant therapy was allowed, as well as one hormonal
treatment regimen for metastatic breast cancer before
randomization. Among the exclusion criteria were treat-
ment for metastatic breast cancer other than that described,
metastases to the central nervous system, decline in LVEF
to below 50 % during or after prior therapy with trast-
uzumab, prior exposure to a cumulative dose of doxoru-
bicin (or its equivalent) of more than 360 mg/m2, and
history of congestive heart failure.
Assessments
Tumour assessments were based on RECIST and per-
formed every 9 weeks. Adverse events were monitored
continuously and graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (NCI-CTCAE) v3.0. LVEF was assessed by echo-
cardiography or multiple-gated acquisition scanning and
the same method was to be used for an individual patient
throughout the study. LVEF measurements took place at
baseline, every 9 weeks during the treatment period, at the
treatment discontinuation visit, every 6 months in the first
year of follow-up, then annually for up to 3 years.
Randomization and masking
Patients were randomly assigned treatment in a 1:1 ratio. A
complete block randomization scheme was applied in order
to balance treatment assignment. Treatment allocation was
stratified by geographic region (Asia, Europe, North
America, and South America) and prior treatment status
(neoadjuvant and/or adjuvant treatment received or not).
An interactive voice response system was utilized to collect
patient screening information and to allocate treatment.
Patient identification numbers were allocated sequentially
in the order in which patients were enrolled. The study was
double-blinded.
Statistical analyses
A sample size of 800 patients was planned for the study and
the primary analysis was defined to take place after 381
independently assessed progression-free survival events had
occurred. With this number of events, it was estimated that
the study had 80 % power to detect a 33 % improvement in
median progression-free survival in the pertuzumab arm
(hazard ratio [HR]: 0.75) at a two-sided significance level of
5 %. The log-rank test, with stratification according to prior
treatment status and region, was used to compare indepen-
dently assessed progression-free survival between both
treatment arms. The Kaplan–Meier approach was used to
estimate the median independently assessed progression-
free survival in each arm. A Cox proportional hazards
model, with stratification according to prior treatment status
and region, was used to estimate the hazard ratio and 95 %
confidence intervals (CIs). To analyze the consistency of the
treatment effect, pre-specified subgroup analyses of pro-
gression-free survival were performed, including age groups
(\65, C65, \75, and C75 years). Adverse events were
reported and analyzed using descriptive methods. The time
to first event of left ventricular systolic dysfunction (LVSD)
was evaluated by the Kaplan–Meier approach. A Cox
regression analysis of time to first LVSD event was per-
formed to investigate pre-defined potential risk factors for
cardiac dysfunction, including age. SAS version 8.2 was
used for statistical analyses. Efficacy analyses were per-
formed according to treatment allocation (intention-to-treat
[ITT] population) and safety analyses were performed as per
treatment received.




In total, 808 patients were enrolled into the study from 204
sites in 25 countries; 406 patients were randomized to the
placebo arm, 402 patients were randomized to the pert-
uzumab arm. In the ITT population, 681 patients (84.3 %)
were younger than 65 years (339 in the placebo arm, 342 in
the pertuzumab arm). There were 127 patients (15.7 %)
65 years of age or older (67 in the placebo arm, 60 in the
pertuzumab arm). Two patients in each arm did not receive
any study treatment. Eight patients randomized to the pla-
cebo arm received at least one dose of pertuzumab. In the
pertuzumab arm, one patient-received treatment allocated to
the placebo arm only. The safety population therefore
comprised 678 patients\65 years (placebo arm: 332; pert-
uzumab arm: 346) and 126 patients C65 years (placebo arm:
65; pertuzumab arm: 61). The data cut-off for the analyses
presented here took place in May 2011. Table 1 presents
disease characteristics at baseline per age group. In both age
groups, a higher proportion of patients randomized to the
pertuzumab arm presented with ECOG performance status
of 0. In patients C65 years, a higher proportion of patients
randomized to the pertuzumab arm presented with non-
visceral disease. In the younger age group, 9.1 % of patients
in the placebo arm and 12.6 % of patients in the pertuzumab
arm had received neoadjuvant or adjuvant treatment with
trastuzumab. For older patients, the proportion of patients
with previous exposure to trastuzumab was 14.9 % in the
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Table 1 Disease characteristics at baseline per age group
n (%) \65 years C65 years
Placebo ? trastuzumab ?
docetaxel (n = 339)
Pertuzumab ? trastuzumab ?
docetaxel (n = 342)
Placebo ? trastuzumab ?
docetaxel (n = 67)
Pertuzumab ? trastuzumab ?
docetaxel (n = 60)
Median age (range),
years
51 (27–64) 53 (22–64) 68 (65–89) 69 (65–82)
ECOG PS
0 208 (61.4) 235 (68.7) 40 (59.7) 39 (65.0)
1 130 (38.3) 105 (30.7) 27 (40.3) 20 (33.3)
2a 0 (0.0) 2 (0.6) 0 (0.0) 1 (1.7)
3a 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Disease type
Visceral disease 261 (77.0) 269 (78.7) 55 (82.1) 45 (75.0)
Non-visceral
disease




5.0 (1–19) 5.0 (1–17) 4.0 (1–16) 4.0 (1–17)





79.0 (10–455) 79.0 (10–422) 79.0 (13–365) 82.5 (10–404)





172 (50.7) 158 (46.2) 27 (40.3) 31 (51.7)
ER- and PgR-
negative
159 (46.9) 183 (53.5) 37 (55.2) 29 (48.3)
Unknown 8 (2.4) 1 (0.3) 3 (4.5) 0 (0.0)
HER2 status by IHC
0 or 1? 2 (0.6) 3 (0.9) 0 (0.0) 1 (1.7)
2? 26 (7.7) 38 (11.1) 6 (9.0) 9 (15.0)
3? 310 (91.4) 300 (87.7) 61 (91.0) 50 (83.3)
Unknown 1 (0.3) 1 (0.3) 0 (0.0) 0 (0.0)
HER2 status by
FISH
Positive 320 (94.4) 326 (95.3) 63 (94.0) 58 (96.7)
Negative 4 (1.2) 1 (0.3) 0 (0.0) 0 (0.0)
Unknown 15 (4.4) 15 (4.4) 4 (6.0) 2 (3.3)
Prior trastuzumab
treatment
31 (9.1) 43 (12.6) 10 (14.9) 4 (6.7)
Prior anthracycline
treatment
140 (41.3) 135 (39.5) 24 (35.8) 15 (25.0)
Prior radiotherapy 141 (41.6) 146 (42.7) 34 (50.7) 25 (41.7)
Median disease-free
intervalb, months
29.0 (0–181) 29.0 (0–186) 28.0 (0–259) 62.0 (18–276)
Number of patients 156 153 31 20
ECOG PS Eastern Cooperative Oncology Group performance status, ER estrogen receptor, FISH fluorescence in situ hybridization, IHC immu-
nohistochemistry, PgR progesterone receptor
a Protocol violation
b Defined as the period between completion of systemic treatment (excluding hormonal therapy) and diagnosis of metastatic disease
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placebo arm and 6.7 % in the pertuzumab arm. A longer
median disease-free interval, defined as the period between
completion of systemic treatment (excluding hormonal
therapy) and diagnosis of metastatic disease, was reported
for patients C65 years in the pertuzumab arm (62 months)
compared with all other subgroups (28 or 29 months). In the
study population, a higher proportion of older compared
with younger patients reported previous (36.2 vs 28.2 %)
and current (85.8 vs 66.7 %) diseases other than breast
cancer at baseline (Online Resource 1).
Efficacy
The analysis of independently assessed progression-free
survival in the whole ITT population demonstrated a
median progression-free survival of 12.4 months in the
placebo arm and 18.5 months in the pertuzumab arm (HR:
0.62; 95 % CI 0.51–0.75; P \ 0.0001) [18]. Exploratory
analyses of independently assessed progression-free sur-
vival by age group (\65, C65, \75, and C75 years) were
pre-defined per protocol. The hazard ratios observed in all
age groups were comparable to the hazard ratio in the
whole ITT population, suggesting that the treatment benefit
observed with pertuzumab is consistent in all analyzed age
groups (Fig. 1a). The wide confidence intervals for the
group of patients C75 years are a consequence of the small
sample size (n = 19). In a post hoc analysis, Kaplan–Meier
estimates for median independently assessed progression-
free survival in patients \65 years and patients C65 years
were calculated (Fig. 1b). In patients younger than
65 years, the median progression-free survival was
12.5 months in the placebo arm and 17.2 months in the
pertuzumab arm (HR: 0.65; 95 % CI 0.53–0.80). In
patients 65 years of age or older, median progression-free
survival was 10.4 months in the placebo arm and
21.6 months in the pertuzumab arm (HR, 0.52; 95 % CI
0.31–0.86) (Table 2).
The objective response rate (complete response plus
partial response), assessed in patients with independently
confirmed measurable disease at baseline, favored treat-
ment in the pertuzumab arm in all age groups (Table 3).
The difference in response rates was 10.8 % points in the
whole ITT population, 11.5 % points in patients\65 years
and 8.1 % points in patients C65 years. The analysis of
objective response rate per age group was exploratory only.
Exposure to docetaxel
In all subgroups, at least 90 % of patients who permanently
discontinued docetaxel completed the recommended
number of at least six cycles of docetaxel (Table 4). The
proportion of patients who discontinued docetaxel due to
an adverse event was generally balanced across subgroups,
although a smaller proportion of patients C65 years in the
pertuzumab arm discontinued docetaxel due to an adverse
event. The median number of docetaxel cycles was com-
parable between treatment arms but lower in older patients
(6.5 and 6.0) compared with the subgroup of younger
patients (8.0 in both arms). Docetaxel dose reductions
below 75 mg/m2 occurred more often in patients 65 years
of age or older than in younger patients, though this did not




























Ptz + T + D <65 Pla + T + D <65 
Ptz + T + D 65 Pla + T + D 65
A
B
Fig. 1 Independently assessed
progression-free survival per
age group. a Hazard ratios and
95 % confidence intervals for
independently assessed
progression-free survival in pre-
specified subgroups according
to age. b Kaplan–Meier
estimates of independently
assessed progression-free
survival in patients \65 years
and patients C65 years
randomized to receive placebo,
trastuzumab, and docetaxel or
pertuzumab, trastuzumab, and
docetaxel. CI confidence
interval, HR hazard ratio,
D docetaxel, Pla placebo, Ptz
pertuzumab, T trastuzumab
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Adverse events
In both age groups, the incidences of diarrhoea, neutropenia,
and dysgeusia (all grades) were higher in the pertuzumab arm
compared with the placebo arm (Table 5). Following the
discontinuation of docetaxel, the incidence of adverse events
fell considerably, with the exception of LVSD. In both age
groups, diarrhoea, fatigue, and rash were reported more fre-
quently in the pertuzumab arm than in the placebo arm fol-
lowing docetaxel discontinuation (Table 5). No episodes of
febrile neutropenia were reported in any arm or age group
after discontinuation of docetaxel. In patients 65 years of age
or older, diarrhoea, fatigue, asthenia, decreased appetite,
vomiting, and dysgeusia (all grades) were reported more
frequently in both treatment arms compared with younger
patients. Neutropenia, on the other hand, was reported less
frequently in the older subgroup of patients.
Adverse events of grade C3 reported more frequently in
the pertuzumab arm in both age groups were febrile neu-
tropenia (especially in the younger subgroup) and diar-
rhoea (especially in older patients) (Table 6). Although
peripheral neuropathy (grade C3) was reported with similar
incidence for both arms in patients\65 years (six patients
in each arm), its incidence was higher in patients
C65 years receiving treatment in the pertuzumab arm (five
patients versus one patient). The incidences of diarrhoea
and fatigue (grade C3) were higher in older patients in
both treatment arms compared with younger patients. In
contrast, grade C3 neutropenia, leukopenia, and febrile
neutropenia were reported less frequently in older patients
compared with the younger subgroup.
The proportion of patients who received medication
with granulocyte-colony-stimulating factors (G-CSFs) was
lower in the older subgroup compared with the younger
subgroup. In patients less than 65 years of age, 114/332
(34.3 %) patients in the placebo arm and 135/346 (39.0 %)
patients in the pertuzumab arm-received G-CSFs. For
patients 65 years of age or older, 19/65 (29.2 %) patients
received medication with G-CSFs in the placebo arm and
12/61 (19.7 %) patients received G-CSFs in the pert-
uzumab arm.
In a univariate Cox regression analysis, age had no sta-
tistically significant association with the development of
asymptomatic or symptomatic LVSD (C65 years vs
\65 years: HR: 1.25; 95 % CI 0.61–2.56; P = 0.5502;
C75 years versus\75 years: HR: 2.25; 95 % CI 0.55–9.29;
P = 0.2606). Due to the low number of LVSD events overall
(n = 51; Table 5), the analysis has limited sensitivity to
detect differences in time to event by age group.
Discussion
We evaluated efficacy and safety of pertuzumab, trast-
uzumab, and docetaxel or placebo, trastuzumab, and
docetaxel as first-line therapy for HER2-positive metastatic
Table 2 Independently
assessed progression-free
survival in the whole study
population and per age group
CI confidence interval, HR
hazard ratio, PFS progression-
free survival
Placebo ? trastuzumab ?
docetaxel
Pertuzumab ? trastuzumab ?
docetaxel
Whole study population, n 406 402
Median PFS, months 12.4 18.5
HR (95 % CI) 0.62 (0.51–0.75)
Patients \65 years, n 339 342
Median PFS, months 12.5 17.2
HR (95 % CI) 0.65 (0.53–0.80)
Patients C65 years, n 67 60
Median PFS, months 10.4 21.6
HR (95 % CI) 0.52 (0.31–0.86)
Table 3 Independently
assessed objective response rate
in patients with measurable
disease at baseline
ORR objective response rate
Placebo ? trastuzumab ?
docetaxel
Pertuzumab ? trastuzumab ?
docetaxel
Whole study population, n 336 343
ORR, n (%) 233 (69.3) 275 (80.2)
P = 0.0011
Patients \65 years, n 278 293
ORR, n (%) 189 (68.0) 233 (79.5)
Patients C65 years, n 58 50
ORR, n (%) 44 (75.9) 42 (84.0)
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breast cancer in patients C65 years compared with patients
\65 years. Treatment with pertuzumab, trastuzumab, and
docetaxel resulted in superior progression-free survival in
both age groups compared with the placebo arm. The long-
median progression-free survival of 21.6 months reported
in patients C65 years in the pertuzumab arm may be based
on some favourable disease characteristics observed in this
subgroup, such as a lower proportion of patients with
previous exposure to trastuzumab, a higher proportion of
patients with non-visceral disease and a longer median
disease-free interval, characteristics that suggest more
indolent disease in these patients. However, the small
sample size limits the interpretation of these observations.
A higher incidence of grade C3 diarrhoea was reported in
older patients treated in the pertuzumab arm, and so
patients receiving this regimen should be closely monitored
in clinical practice. The dose of docetaxel was reduced
more frequently and the median number of docetaxel
cycles was lower (6.5 and 6.0 cycles per arm) in older
patients, which probably explains the lower incidence of
neutropenia and febrile neutropenia, as well as less fre-
quent use of G-CSFs. These observations suggest that
toxicities were more often managed by docetaxel dose
adjustments in patients C65 years than in younger patients.
Nevertheless, the median number of docetaxel cycles
administered in older patients complies with the per-pro-
tocol recommendation of at least six cycles, and C90 % of
patients who permanently discontinued docetaxel had
received at least six cycles of docetaxel. It is interesting to
note that, despite more frequent docetaxel dose reductions
and a lower median number of docetaxel cycles, the overall
efficacy outcomes of older patients were similar to those of
younger patients, which raises the question about the
optimal duration of chemotherapy when it is combined
with HER2-targeted treatment.
The combination of pertuzumab with trastuzumab in
CLEOPATRA did not increase the risk of cardiac dysfunc-
tion associated with trastuzumab [22], and there was no
Table 4 Exposure to docetaxel treatment
\65 years C65 years
Placebo ? trastuzumab ?
docetaxel (n = 332)
Pertuzumab ? trastuzumab ?
docetaxel (n = 346)
Placebo ? trastuzumab ?
docetaxel (n = 65)
Pertuzumab ? trastuzumab ?





8.0 (1–41) 8.0 (1–35) 6.5 (1–26) 6.0 (1–16)
Median dose intensity,
mg/m2/week












No, n (%) 117 (35.2) 97 (28.0) 25 (38.5) 12 (19.7)









Standard practice 127/215 (59.1) 140/249 (56.2) 22/40 (55.0) 37/49 (75.5)
Adverse event 75/215 (34.9) 85/249 (34.1) 15/40 (37.5) 12/49 (24.5)
Refused
treatment
6/215 (2.8) 12/249 (4.8) 1/40 (2.5) 0/49 (0.0)
Other 7/215 (3.3) 12/249 (4.8) 2/40 (5.0) 0/49 (0.0)
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evidence of late or cumulative cardiac toxicity after an
additional year of follow-up [19]. Although older patients are
at increased risk of congestive heart failure, we could not find
a significant correlation of age with the development of
asymptomatic or symptomatic LVSD. Nevertheless, routine
monitoring of cardiac function in patients receiving trast-
uzumab and pertuzumab is recommended.
Due to the increase in life expectancy, the number of
older patients with breast cancer will rise and treatment
decisions should be based on an acceptable benefit–risk
ratio. According to data from 2011 in the US, women aged
65–69 and 70–74 years have a life expectancy of about 20
and 16 years, respectively [23]. Underestimation of a
patient’s life expectancy and of their general physical
ability may result in erroneous decisions to treat less
aggressively, exposing the patient to an unnecessary risk of
breast cancer-related death. However, the higher frequency
of co-morbidities, mainly hypertension, arthritis, and heart
diseases [7], in older patients with breast cancer is an
equally important consideration for disease management.
Studies have shown that older patients derive a similar
benefit from chemotherapy to younger patients [24–26],
but that they are more vulnerable to chemotherapy-related
toxicities [24, 27, 28]. In their updated recommendations
for the management of elderly patients with breast cancer
the International Society of Geriatric Oncology (SIOG) and
European Society of Breast Cancer Specialists (EUSOMA)
emphasize that chronological age alone should not be a
determinant for the treatment of breast cancer [29]. Deci-
sions regarding treatment should rather be based on phys-
iological age (fitness), estimated life expectancy, risks,
benefits, treatment tolerance, patient preference, and
potential treatment barriers [29]. In addition, an (abbrevi-
ated) comprehensive geriatric assessment may help guide
informed treatment decisions for older patients with breast
cancer [29].
Based on the efficacy benefit and the adverse events
profile observed in CLEOPATRA, we suggest that the use
of pertuzumab, trastuzumab, and docetaxel should not be
limited by age, though proactive management of toxicities
and regular cardiac monitoring should clearly be under-
taken. At present, population-based data with the combi-
nation of pertuzumab and trastuzumab are limited due to its
very recent approval. More evidence on the tolerability and
efficacy of pertuzumab and trastuzumab in HER2-positive
metastatic breast cancer in combination with different
chemotherapy partners and aromatase inhibitors in patients
with hormone receptor-positive disease will be obtained in
several clinical trials currently ongoing (NCT01572038,
NCT01026142, NCT01565083, NCT01491737).
Table 6 Ten most common grade C3 adverse events overall
n (%) \65 years C65 years
Placebo ? trastuzumab ?
docetaxel (n = 332)
Pertuzumab ? trastuzumab ?
docetaxel (n = 346)
Placebo ? trastuzumab ?
docetaxel (n = 65)
Pertuzumab ? trastuzumab ?











184 (55.4) 210 (60.7) 31 (47.7) 30 (49.2)
Neutropenia 156 (47.0) 174 (50.3) 26 (40.0) 25 (41.0)
Leukopenia 51 (15.4) 44 (12.7) 7 (10.8) 6 (9.8)
Febrile
neutropenia
26 (7.8) 51 (14.7) 4 (6.2) 5 (8.2)
Diarrhoea 16 (4.8) 23 (6.6) 4 (6.2) 9 (14.8)
Anaemia 9 (2.7) 10 (2.9) 5 (7.7) 0 (0.0)
Fatigue 9 (2.7) 7 (2.0) 4 (6.2) 2 (3.3)
Peripheral
neuropathy
6 (1.8) 6 (1.7) 1 (1.5) 5 (8.2)
LVSD 8 (2.4) 4 (1.2) 3 (4.6) 1 (1.6)
Asthenia 4 (1.2) 10 (2.9) 2 (3.1) 0 (0.0)
Granulocytopenia 9 (2.7) 4 (1.2) 0 (0.0) 2 (3.3)
LVSD left ventricular systolic dysfunction
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